John Day
VerifiedStanford University · Rheumatology
Active 1932–2026
About
John Day is a Professor of Neurology, of Pediatrics, and, by courtesy, of Pathology at Stanford University. He is affiliated with the Center for Artificial Intelligence in Medicine & Imaging (AIMI) at Stanford. His work focuses on the intersection of artificial intelligence and medicine, particularly in developing innovative imaging and diagnostic techniques. As a faculty member at Stanford, he contributes to advancing research in medical AI applications, fostering collaborations across disciplines, and supporting educational initiatives in health AI.
Research topics
- Medicine
- Physical medicine and rehabilitation
- Internal medicine
- Pathology
- Anatomy
- Pediatrics
- Physical therapy
Selected publications
Heart Rhythm · 2026-04-01
articleOpen accessHeart Rhythm · 2026-04-01
articleThe Lancet Neurology · 2026-01-22 · 3 citations
articleOpen accessBACKGROUND: Herpes simplex virus (HSV) encephalitis is characterised by inflammation and swelling of the brain, resulting in death or severe neurocognitive sequelae. HSV encephalitis is treated with the antiviral aciclovir but still has substantial mortality and morbidity. Adjunct corticosteroids are sometimes used, but whether they improve the outcome is unclear. We aimed to establish the safety and efficacy of adjunct corticosteroids in HSV encephalitis. METHODS: In this multicentre, observer-blind, randomised, phase 3 trial, adults with HSV encephalitis admitted to 53 hospitals in the UK were randomly assigned to receive intravenous dexamethasone (10 mg/kg, four times daily for 4 days) plus intravenous aciclovir (10 mg/kg three times daily for at least 14 days; dexamethasone group), or intravenous aciclovir alone (control group). Eligible patients aged 16 years or older had suspected encephalitis (a febrile illness with new onset seizure, new focal neurological signs or alteration in consciousness, cognition, personality, or behaviour), with positive HSV type 1 or type 2 PCR test in CSF. Participants were randomly assigned by the trial team at the recruiting site, using a secure web-based randomisation programme. The primary outcome was verbal memory score at 26 weeks, measured by the Wechsler Memory Scale (WMS)-IV auditory memory index. Analyses of primary and secondary outcomes were performed according to the modified intention-to-treat principle, and safety analyses were based on whether participants received at least one dose of the study drug. Trial neuropsychologists assessing the primary outcome, and statisticians involved in the study's primary outcome, were masked to treatment group allocation. The trial is registered with the International Standard Randomised Controlled Trial Number Registry, ISRCTN11774734, and EudraCT, EudraCT2016-004835-19, and is completed. FINDINGS: Between Sept 22, 2016, and Feb 2, 2022, 94 patients with HSV encephalitis were recruited, 47 (20 [43%] female and 27 [57%] male) to the dexamethasone group, and 47 (24 [51%] female and 23 [49%] male) to the control group. Dexamethasone was initiated a median 7 (IQR 4-8) days after hospital admission. Seven patients withdrew consent, and six were lost to follow-up. Thus, 81 were included in the modified intention-to-treat analysis (39 in the treatment group and 42 in the control group). The primary outcome, verbal memory score at 26 weeks, did not differ significantly between the groups (71 [SD 26] in the dexamethasone group, and 69 [SD 25] in the control group; adjusted difference 1·77 [95% CI -9·57 to 13·12; p=0·76). There were 27 adverse events involving 18 (38%) participants in the control group, and 25 adverse events involving 18 (40%) participants in the dexamethasone group. The most common serious adverse events were seizures requiring readmission to hospital (affecting one [2%] patient in the dexamethasone group and one [2%] patient in the control group) and thrombotic events, including deep vein thrombosis (affecting one [2%] patient in the dexamethasone group) and pulmonary embolism (affecting one [2%]patient in the dexamethasone group). There were no treatment-related deaths. INTERPRETATION: In adults with HSV encephalitis, dexamethasone plus aciclovir had a satisfactory safety profile but did not improve verbal memory score compared with aciclovir alone. Given the established role of corticosteroids in other inflammatory encephalitides, our findings suggest that their early use in suspected encephalitis is unlikely to be harmful. Future studies should assess more targeted immunomodulatory approaches in HSV encephalitis. FUNDING: National Institute for Health and Care Research.
Heart Rhythm · 2026-04-01
articleHeart Rhythm · 2026-04-01
articleHeart Rhythm · 2026-04-01
articleHeart Rhythm · 2026-04-01
articleHeart Rhythm · 2026-04-01
articleHeart Rhythm · 2026-04-01
articleHeart Rhythm · 2026-04-01
article
Recent grants
Myotonic Dystrophy: Molecular Pathophysiology and CNS Effects
NIH · $26.2M · 2008–2019
NIH · $209k · 1989
NIH · $21.0M · 2010
NIH · $1.6M · 2013
Frequent coauthors
- 580 shared
Mary M. Reilly
National Hospital for Neurology and Neurosurgery
- 573 shared
Sabrina W. Yum
- 570 shared
Michael E. Shy
University of Iowa
- 567 shared
Davide Pareyson
Sydney Children’s Hospitals Network
- 567 shared
Matilde Laurá
National Hospital for Neurology and Neurosurgery
- 566 shared
David N. Herrmann
- 565 shared
Joshua Burns
Sydney Children’s Hospitals Network
- 565 shared
Steven S. Scherer
University of Pennsylvania
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with John Day
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup